## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Quality metrics strong (ROE 62%). Caution: momentum weakening (-3.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($113.30)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. DaVita Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh**
- Source: TradingView | 20251130T163633 | Neutral | Relevance: 98%
- This page provides financial data for DaVita Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh (DVAI34) on TradingView, specifically focusing on tangible book value per share. It displays market status, links to supercharts and various financial overview sections, and details data source attributions for market and reference information.

**2. Catalyzing Change in Specialty Care: DaVita Shares Vision for Technology Transformation**
- Source: Yahoo Finance | 20251202T153500 | Bullish | Relevance: 98%
- DaVita (DVA) highlights its vision for leveraging technology to transform specialty care, addressing the fragmentation prevalent in chronic disease management. Joel Haugen, chief product officer, emphasized that specialty care accounts for 90% of medical spend and showcased DaVita Care Connect as an example of technology enhancing patient engagement, adherence, and overall experience. The company stresses the importance of designing user-friendly solutions for both patients and care teams, as well as fostering collaboration among stakeholders to scale these technological advancements.

**3. Catalyzing Change in Specialty Care: DaVita Shares Vision for Technology Transformation**
- Source: ACCESS Newswire | 20251202T103500 | Bullish | Relevance: 97%
- DaVita shared its vision for technology transformation in specialty care, emphasizing how technology can help address healthcare fragmentation for the 129 million Americans living with chronic conditions. Joel Haugen, Chief Product Officer for DaVita, highlighted the significant medical spend in specialty care and the potential of solutions like the DaVita Care Connect mobile app to enhance patient engagement through user-friendly interfaces. The article stresses the need for intentional change, prioritizing the experience of both patients and care teams, and fostering collaboration among stakeholders to scale solutions and reduce care fragmentation.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 13.1% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 9.4x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.5B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 9.4 |
| Current P/E | 11.2 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.2% to -2.4% (-3.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.41% (CS: 31) | Weak |
| RSI_14 | 44.1 | Neutral |
| MACD Histogram | 0.36 | Bullish |
| vs SMA20 | 0.993x | Below |
| vs SMA50 | 0.955x | Below |
| vs SMA200 | 0.869x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $119.18
- **Stop Loss:** $113.30 (4.9% risk)
- **Target:** $130.94 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $20,260.60
- **Portfolio %:** 20.26%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*